New pill combo targets Hard-to-Treat cancers in early trial
NCT ID NCT03875287
First seen Jan 12, 2026 · Last updated May 07, 2026 · Updated 14 times
Summary
This early-phase study tests a new two-drug combination taken by mouth for people with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and understand side effects. Up to 35 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231, United States
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90089, United States
Conditions
Explore the condition pages connected to this study.